Sugi Predict

Sugi Predict / Compounds / SCHEMBL16635189

SCHEMBL16635189

SCHEMBL16635189

OB(O)c1ccc(C(F)(F)F)cc1OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LIPE Q05469 2/20 0.60
▸ RXRA P19793 2/20 0.54
▸ RXRB P28702 2/20 0.54
▸ RXRG P48443 2/20 0.54
▸ HTR2C P28335 1/20 0.53
▸ SLC6A4 P31645 1/20 0.53
▸ HTR2B P41595 1/20 0.53
▸ ENPP2 Q13822 1/20 0.48
▸ MRGPRX4 Q96LA9 6/20 0.46
▸ LRRK2 Q5S007 3/20 0.46
▸ PTPN1 P18031 2/20 0.46
▸ PTPN6 P29350 2/20 0.46
▸ PTPN2 P17706 1/20 0.46
▸ PTGER1 P34995 1/20 0.44
▸ KEAP1 Q14145 1/20 0.44
▸ NFE2L2 Q16236 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31043388 1.00 LIPE (0.60) LIPERXRARXRBRXRGHTR2C
SCHEMBL29952290 0.89 LIPE (0.60) LIPERXRARXRBRXRGHTR2C
SCHEMBL1950920 0.89 LIPE (0.60) LIPERXRARXRBRXRGHTR2C
SCHEMBL28074627 0.82 HTR2C (0.55) LIPERXRARXRBRXRGHTR2C
SCHEMBL538233 0.81 RXRA (0.57) RXRARXRBRXRGHTR2CSLC6A4
SCHEMBL1954543 0.81 LIPE (0.71) LIPEENPP2MRGPRX4PTGER1
SCHEMBL30573038 0.81 HTR2C (0.56) RXRARXRBRXRGHTR2CSLC6A4
SCHEMBL29953622 0.81 LIPE (0.71) LIPEENPP2MRGPRX4PTGER1
SCHEMBL12167392 0.81 HTR2C (0.56) RXRARXRBRXRGHTR2CSLC6A4
SCHEMBL29953373 0.80 CYP2C19 (0.51) LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4562009-A1 NOVEL COMPOUNDS AC Immune SA (CH) 2025-06-04 — — EP disclosed
WO-2024141535-A1 NLRP3 INFLAMMASOME INHIBITORS ASTRAZENECA AB (SE) 2024-07-04 — — WO disclosed
US-20240101563-A1 NOVEL COMPOUNDS AC IMMUNE SA (CH) 2024-03-28 — — US disclosed
WO-2024023266-A1 NOVEL COMPOUNDS AC IMMUNE SA (CH) 2024-02-01 — — WO disclosed
US-11236046-B2 Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators GENENTECH, INC. (US) 2022-02-01 — — US disclosed
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same EA PHARMA CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20200048197-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS GENENTECH, INC. (US) 2020-02-13 — — US disclosed
CN-106458952-B Heterocycle sulfamide derivatives and drug containing the heterocycle sulfamide derivatives EA制药株式会社 2019-09-27 — — CN disclosed
EP-3101015-B1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO LTD (JP) 2019-09-18 — — EP disclosed
EP-3055302-B1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS HOFFMANN LA ROCHE (CH) 2018-12-26 — — EP disclosed
US-20180282272-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS GENENTECH, INC. (US) 2018-10-04 — — US disclosed
US-20180118680-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS GENENTECH, INC. (US) 2018-05-03 — — US disclosed
CN-106458952-A Heterocyclic sulfonamide derivative and medicine comprising same EA制药株式会社 2017-02-22 — — CN disclosed
EP-3101015-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA Pharma Co., Ltd. (JP) 2016-12-07 — — EP disclosed
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO., LTD. (JP) 2016-11-17 — — US disclosed
EP-3055302-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS F. Hoffmann-La Roche AG (CH) 2016-08-17 — — EP disclosed
US-20160221945-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS GENENTECH, INC. (US) 2016-08-04 — — US disclosed
WO-2015052264-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221945-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 LIPE 4501/4885RXRA 2751/4885RXRB 2806/4885
US-20180282272-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 LIPE 4501/4885RXRA 2751/4885RXRB 2806/4885
US-20180118680-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 LIPE 4501/4885RXRA 2751/4885RXRB 2806/4885
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME TRPA1, TRPV1, TRPV2 LIPE 3573/4885RXRA 1187/4885RXRB 1304/4885
US-20200048197-A1 SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS TRPA1, TRPV1, TRPV2 LIPE 4501/4885RXRA 2751/4885RXRB 2806/4885
US-20240101563-A1 NOVEL COMPOUNDS NLRP3, NOD1, NLRP1 LIPE 3341/4885RXRA 1104/4885RXRB 766/4885
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same TRPA1, TRPV1, TRPV2 LIPE 3573/4885RXRA 1187/4885RXRB 1304/4885
US-11236046-B2 Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators TRPA1, TRPV1, TRPV2 LIPE 4501/4885RXRA 2751/4885RXRB 2806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.